IGI’s new drug candidate ISB 2301 to target solid tumors
The company intends to file an IND submission by the end of this year and begin clinical studies in 2027
The company intends to file an IND submission by the end of this year and begin clinical studies in 2027
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged
The protections extend through at least 2035, with the potential for further extensions
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
These abstracts report on the company's three lead drug candidates, including olverembatinib
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
Subscribe To Our Newsletter & Stay Updated